Cancer chemotherapy can cause nausea and vomiting in patients undergoing treatment. The nausea and vomiting associated with chemotherapy affects patient compliance and health. Cancer chemotherapy associated nausea and vomiting therapeutics help prevent and manage these side effects in cancer patients. Therapeutics include 5-HT3 receptor antagonists, NK1 receptor antagonists, corticosteroids, cannabis-based medicines, and other drugs. They provide relief by blocking the neurochemical pathways in the brain that trigger nausea and vomiting.
The global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market is estimated to be valued at US$ 3537.91 Mn in 2023 and is expected to exhibit a CAGR of 5.3% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The cancer chemotherapy associated nausea and vomiting therapeutics market is witnessing strong growth driven by new product launches and FDA approvals. Major companies are investing heavily in research and development of novel and improved therapies to manage chemotherapy-induced nausea and vomiting. In 2021, Helsinn Therapeutics, Inc. received FDA approval for Odiferous (Sustol) for severe acute and delayed CINV in adults. Odiferous provides sustained 24-hour coverage of nausea and vomiting through subcutaneous injection. Similarly, Camurus received FDA approval for weekly Flixenadine for prevention of CINV. Such new product approvals are expanding treatment options and driving the market growth.
Market Segment Analysis
The global cancer chemotherapy associated nausea and vomiting therapeutics market is segmented on the basis of drug type, distribution channel, and geography. By drug type, the market is segmented into 5-HT3 receptor antagonists, NK1 receptor antagonists, other drug classes. Among these, 5-HT3 receptor antagonists dominates the market as these drugs helps to counteract CINV by blocking serotonin (5-HT3) receptors located in the gastrointestinal tract and are used as first line agents in the treatment of CINV.
Key Takeaways
The global Cancer Chemotherapy Associated Nausea And Vomiting Therapeutics Market Size is estimated to be valued at US$ 3537.91 Mn in 2023 and is expected to exhibit a CAGR of 5.3% over the forecast period 2024 to 2031.
Regional analysis: North America region is expected to register fastest growth during the forecast period owing to rising prevalence of cancer and increasing use of chemotherapy in treatment. The market in Asia Pacific is expected to grow at a significant pace due to growing geriatric population, improving healthcare infrastructure in developing countries, and rising healthcare spending.
Key players: Key players operating in the cancer chemotherapy associated nausea and vomiting therapeutics market are Nature Essential Foods Pvt Ltd, Lotus Bakeries, General Mills Inc., Clif Bar & Company, ProBar LLC, Post Holdings Inc., BumbleBar Inc., PepsiCo Inc., Eat Anytime, TORQ Limited, OTE Sports Ltd, Kind LLC, Science in Sports PLC, and Kellogg Company.
Explore more related article on this topic: https://www.ukwebwire.com/cancer-chemotherapy-associated-nausea-and-vomiting-therapeutics/
Comments
0 comment